JDD Re:View: Recent Advances in Acne and Rosacea Management
Dermatological practice frequently centers on the management of acne and rosacea. Although initial therapeutic strategies often appear linear, clinical challenges arise when primary interventions prove insufficient, necessitating a sophisticated grasp of pathophysiology and the therapeutic armamentarium. In this installment of JDD Re:View, we evaluate pivotal research focused on the latest developments in acne and rosacea care.
Effective acne management requires a nuanced appreciation of its multifactorial etiology. A 2024 publication by Del Rosso et al. offers fresh perspectives on systemic inflammatory drivers, investigating the roles of hormonal fluctuations, dietary patterns, oxidative stress, and the microbiome. These insights suggest that while pharmacological therapy remains fundamental, lifestyle modifications significantly augment patient outcomes. Complementing this, Feldman et al. conducted an analysis of various fixed-combination topicals during the initial four-week treatment window. Their findings regarding benzoyl peroxide, clindamycin, and retinoid pairings provide a roadmap for achieving rapid clinical improvement in inflammatory lesions. For cases advancing to higher severity, Harper et al. present a comprehensive systematic review and network meta-analysis. By synthesizing data from more than 80 trials, they establish a hierarchy of efficacy for moderate-to-severe disease. Finally, Issa et al. provide a holistic perspective on the current therapeutic landscape, bridging the gap between molecular mechanisms and clinical practice.
The management of rosacea presents distinct challenges, particularly regarding treatment resistance and the complexities of insurance reimbursement. The therapeutic spectrum is broad, encompassing systemic and topical antibiotics, antiparasitics, and light-based modalities like the pulsed dye laser. Navigating the logistics of care is facilitated by Friedman et al., whose cross-sectional review clarifies the formulary status of various topical rosacea therapies, from established azelaic acid to modern minocycline formulations. In a related study, the same team explores vessel-targeting interventions specifically for the erythematotelangiectatic variant. This research is particularly vital given the chronic nature of the condition and the historical scarcity of durable treatment options for persistent facial redness.
Ultimately, while these conditions are commonplace, their presentations are highly individualized. Maintaining a commitment to current literature and emerging mechanistic insights is paramount for clinicians striving to deliver optimized, evidence-based dermatologic care.
Treatments for Moderate-to-Severe Acne Vulgaris: A Systematic Review and Network Meta-analysis
Topical Acne Treatment: What’s Behind the Scenes in 2024
Vessel-Targeting Therapies for the Management of Rosacea: A Review of Current Evidence
